Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Ocuphire Pharma Inc
Healthcare
P/NCAV
0.67x
Ticker
OCUP
Exchange
NASDAQ
Country
United States
Close
1.54 $
Mkt Cap
33.2M $
EV
-17.3M $
NCAV Burn Rate
-7.9%
Current Ratio
13.35
Debt/Equity
0.0
EV/REV
-0.91x
EV/EBIT
1.6x
EV/FCF
15.5x
Dilution
57.2% p.A
Total Net Income
-163.9M $
Cheapness
62.0%
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average